New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management
Authors
Keywords
-
Journal
Expert Review of Clinical Immunology
Volume 14, Issue 4, Pages 259-273
Publisher
Informa UK Limited
Online
2018-03-20
DOI
10.1080/1744666x.2018.1454835
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
- (2018) Zenas Z.N. Yiu et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Development of paradoxical inflammatory disorders during treatment of psoriasis with TNF inhibitors: a review of published cases
- (2017) Martin Havmose et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry
- (2017) Paula Dávila-Seijo et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry
- (2017) David Fiorentino et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials
- (2017) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
- (2017) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti–tumor necrosis factor agents versus classic therapies: Prospective meta-analysis of Psonet registries
- (2017) Ignacio Garcia-Doval et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study
- (2017) J.R. Georgakopoulos et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
- (2017) Kristian Reich et al. LANCET
- Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
- (2017) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis
- (2016) F. Gómez-García et al. BRITISH JOURNAL OF DERMATOLOGY
- A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Premedication prevents infusion reactions and improves retention rate during infliximab treatment
- (2016) Francesca Bartoli et al. CLINICAL RHEUMATOLOGY
- Safety of secukinumab in the treatment of psoriasis
- (2016) Andrew Blauvelt Expert Opinion On Drug Safety
- Certolizumab treatment during late pregnancy in patients with rheumatic diseases: Low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients
- (2016) Frauke Förger et al. JOINT BONE SPINE
- Demyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: A review
- (2016) Tian Hao Zhu et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study
- (2016) Eva Havrdová et al. JOURNAL OF NEUROLOGY
- Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS
- (2016) Stephanie M. Gallitano et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
- (2016) Peter C.M. van de Kerkhof et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
- (2016) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of psoriasis patients with hepatitis B or hepatitis C virus infection
- (2016) Claudio Bonifati et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest
- (2015) K. Reich et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- Are Anti-TNF-α Agents Safe for Treating Psoriasis in Hepatitis C Virus Patients with Advanced Liver Disease? Case Reports and Review of the Literature
- (2015) Sergio Di Nuzzo et al. DERMATOLOGY
- Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic
- (2015) Eric Sorenson et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Booster influenza vaccination does not improve immune response in adult inflammatory bowel disease patients treated with immunosuppressives: a randomized controlled trial
- (2015) Hiroko Matsumoto et al. JOURNAL OF GASTROENTEROLOGY
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
- (2015) Mark Lebwohl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Paradoxical psoriasiform reactions to anti-TNFα drugs are associated with genetic polymorphisms in patients with psoriasis
- (2015) T Cabaleiro et al. PHARMACOGENOMICS JOURNAL
- Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis
- (2015) Robert E. Kalb et al. JAMA Dermatology
- EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
- (2015) JOURNAL OF HEPATOLOGY
- Demyelination in a patient receiving ustekinumab for refractory Crohn's disease: Figure 1
- (2014) Yaeesh Badat et al. Journal of Crohns & Colitis
- Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection
- (2014) H. Saeki et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry
- (2014) G. Carretero et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort
- (2014) O. Ahlehoff et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C
- (2013) H.-Y. Chiu et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials
- (2013) J. Schmitt et al. BRITISH JOURNAL OF DERMATOLOGY
- Antidrug antibodies in psoriasis: a systematic review
- (2013) L. Hsu et al. BRITISH JOURNAL OF DERMATOLOGY
- Selective TNF-α inhibitor-induced injection site reactions
- (2013) Giuseppe Murdaca et al. Expert Opinion On Drug Safety
- From the Medical Board of the National Psoriasis Foundation: Vaccination in adult patients on systemic therapy for psoriasis
- (2013) Lara Wine-Lee et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in psoriasis: Results of a pilot study
- (2013) Hajnalka Jókai et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies
- (2013) Jeremy Hugh et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies
- (2013) C. Pouplard et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Efficacy of Hepatitis B Vaccination and Revaccination and Factors Impacting on Response in Patients With Inflammatory Bowel Disease
- (2012) J P Gisbert et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
- (2012) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Peripheral Lymph Node Recurrence of Tuberculosis After Ustekinumab Treatment
- (2012) Ana I. Sánchez-Moya et al. ARCHIVES OF DERMATOLOGY
- Association Between Tumor Necrosis Factor Inhibitor Therapy and Myocardial Infarction Risk in Patients With Psoriasis
- (2012) Jashin J. Wu et al. ARCHIVES OF DERMATOLOGY
- Emerging data on the use of anti-tumor necrosis factor-alpha medications in pregnancy
- (2012) Christina D. Chambers et al. BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
- The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection
- (2012) T.-F. Tsai et al. BRITISH JOURNAL OF DERMATOLOGY
- A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial
- (2012) T.-F. Tsai et al. BRITISH JOURNAL OF DERMATOLOGY
- Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient
- (2012) J. Koskinas et al. BRITISH JOURNAL OF DERMATOLOGY
- Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting
- (2012) R. Navarro et al. BRITISH JOURNAL OF DERMATOLOGY
- Treatment with the Interleukin-17A-Blocking Antibody Secukinumab Does Not Interfere with the Efficacy of Influenza and Meningococcal Vaccinations in Healthy Subjects: Results of an Open-Label, Parallel-Group, Randomized Single-Center Study
- (2012) A. Chioato et al. Clinical and Vaccine Immunology
- Association Between Vaccination for Herpes Zoster and Risk of Herpes Zoster Infection Among Older Patients With Selected Immune-Mediated Diseases
- (2012) Jie Zhang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Differential Risk of Tuberculosis Reactivation among Anti-TNF Therapies Is Due to Drug Binding Kinetics and Permeability
- (2012) M. Fallahi-Sichani et al. JOURNAL OF IMMUNOLOGY
- Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence
- (2012) Rosa Parisi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management
- (2012) Amanda Abramson et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials
- (2012) T. Tzellos et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Injection-site reaction to etanercept: role of skin test in the diagnosis of such reaction and successful desensitization
- (2011) S. Bavbek et al. ALLERGY
- Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors
- (2011) Meliha Crnkic Kapetanovic et al. ARTHRITIS AND RHEUMATISM
- Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies
- (2011) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- Hepatitis-B-Reaktivierung unter TNF-α-Blocker- Therapie mit Adalimumab bei Psoriasis-Arthritis
- (2011) M. Kouba et al. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT
- Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events
- (2011) Caitriona Ryan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Ustekinumab for the treatment of HIV psoriasis
- (2011) Vasileios Paparizos et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: A case series in Taiwan
- (2011) Yung-Tsu CHO et al. JOURNAL OF DERMATOLOGY
- The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study
- (2011) Jie Zhang et al. ARTHRITIS RESEARCH & THERAPY
- TNF-α Antagonism with Etanercept Decreases Glucose and Increases the Proportion of High Molecular Weight Adiponectin in Obese Subjects with Features of the Metabolic Syndrome
- (2010) Takara L. Stanley et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Neurological adverse events associated with anti-tumor necrosis factor alpha treatment
- (2010) Antonio G. Tristano JOURNAL OF NEUROLOGY
- Psoriatic Skin Lesions Induced by Tumor Necrosis Factor Antagonist Therapy: Clinical Features and Possible Immunopathogenesis
- (2010) Angelique N. Collamer et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Tumor Necrosis Factor-α Inhibitor-Induced Psoriasis or Psoriasiform Exanthemata
- (2009) Uwe Wollina et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
- (2009) W. G. Dixon et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective french research axed on tolerance of biotherapies registry
- (2009) F. Tubach et al. ARTHRITIS AND RHEUMATISM
- Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFα blockers: Safety and immunogenicity
- (2009) S. Salemi et al. CLINICAL IMMUNOLOGY
- Effects of tumor necrosis factor-α blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis
- (2009) Jennifer Channual et al. Dermatologic Therapy
- Tuberculin Skin Test Overestimates Tuberculosis Hypersensitivity in Adult Patients with Psoriasis
- (2009) G. Tsiouri et al. DERMATOLOGY
- Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database
- (2009) N. N. Mehta et al. EUROPEAN HEART JOURNAL
- Cutaneous side effects of anti–tumor necrosis factor biologic therapy: A clinical review
- (2009) Aikaterini-Evaggelia Moustou et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Placental Transport of Immunoglobulins: A Clinical Review for Gastroenterologists Who Prescribe Therapeutic Monoclonal Antibodies to Women During Conception and Pregnancy
- (2008) Sunanda V Kane et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer
- (2008) E. R. Brown et al. ANNALS OF ONCOLOGY
- Immediate Type I Hypersensitivity Response Implicated in Worsening Injection Site Reactions to Adalimumab
- (2008) Michael Paltiel et al. ARCHIVES OF DERMATOLOGY
- Successful Treatment With Etanercept of von Zumbusch Pustular Psoriasis in a Patient With Human Immunodeficiency Virus
- (2008) Maryann Mikhail ARCHIVES OF DERMATOLOGY
- Review and expert opinion on prevention and treatment of infliximab-related infusion reactions
- (2008) L.L.A. Lecluse et al. BRITISH JOURNAL OF DERMATOLOGY
- Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis
- (2008) B. Strober et al. BRITISH JOURNAL OF DERMATOLOGY
- Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases
- (2008) Justin M. Ko et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Tuberculosis in the age of biologic therapy
- (2008) Claudia Hernandez et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
- (2008) Craig L Leonardi et al. LANCET
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
- (2008) Kim A Papp et al. LANCET
- Tumour necrosis factor antagonists: structure, function, and tuberculosis risks
- (2008) Robert S Wallis LANCET INFECTIOUS DISEASES
- Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study
- (2008) Benjamin M Segal et al. LANCET NEUROLOGY
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
- (2007) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Tumor necrosis factor-α antagonists and neuropathy
- (2007) Joerg-Patrick Stübgen MUSCLE & NERVE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now